We are live on ! Find out more
IGMS

IGM Biosciences
IGMS

Delisted

IGMS was delisted on the 13th of August, 2025.

Back to rankings

87 hedge funds and large institutions have $220M invested in IGM Biosciences in 2024 Q1 according to their latest regulatory filings, with 26 funds opening new positions, 21 increasing their positions, 23 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

136% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 11

118% more call options, than puts

Call options by funds: $107K | Put options by funds: $49K

21% more funds holding

Funds holding: 72 → 87 (+15)

20% more capital invested

Capital invested by funds: $183M → $220M (+$37.4M)

1.66% more ownership

Funds ownership: 66.9% → 68.57% (+1.7%)

9% less repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 23

Holders
87
Holders Change
+15
Holders Change %
+20.83%
% of All Funds
1.25%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
26
Increased
21
Reduced
23
Closed
11
Calls
$107K
Puts
$49K
Net Calls
+$58K
Net Calls Change
-$132K

Top Buyers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$7.28M
2
Millennium Management
Millennium Management
New York
+$5.19M
3
BBA
Baker Bros. Advisors
New York
+$4.6M
4
Goldman Sachs
Goldman Sachs
New York
+$2.76M
5
RG
Redmile Group
California
+$1.17M

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$4.42M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$3.32M
3
Citadel Advisors
Citadel Advisors
Florida
-$2.3M
4
EAM
Exome Asset Management
New York
-$1.13M
5
Hudson Bay Capital Management
Hudson Bay Capital Management
Connecticut
-$1.03M
Name Holding Trade Value Shares
Change 		Change in
Stake
Wellington Management Group
26
Wellington Management Group
Massachusetts
$552K +$663K +57,190 New
Bank of New York Mellon
27
Bank of New York Mellon
New York
$478K -$28.3K -2,444 -5%
Renaissance Technologies
28
Renaissance Technologies
New York
$464K +$133K +11,500 +31%
EBA
29
Eagle Bay Advisors
New York
$431K – – –
N
30
Nuveen
North Carolina
$393K -$105K -9,074 -18%
Dimensional Fund Advisors
31
Dimensional Fund Advisors
Texas
$381K – – –
AllianceBernstein
32
AllianceBernstein
Tennessee
$312K – – –
Jane Street
33
Jane Street
New York
$300K -$52.3K -4,515 -13%
SPS
34
Susquehanna Portfolio Strategies
Pennsylvania
$292K – – –
ETC
35
Exchange Traded Concepts
Oklahoma
$270K +$103K +8,887 +47%
SFI
36
Susquehanna Fundamental Investments
Pennsylvania
$268K +$321K +27,731 New
TI
37
Trexquant Investment
Connecticut
$233K +$280K +24,177 New
PAM
38
Panagora Asset Management
Massachusetts
$225K -$80.6K -6,954 -23%
Bank of America
39
Bank of America
North Carolina
$215K -$28.5K -2,460 -10%
ECM
40
ExodusPoint Capital Management
New York
$196K +$236K +20,323 New
RhumbLine Advisers
41
RhumbLine Advisers
Massachusetts
$194K +$10.3K +887 +5%
Walleye Capital
42
Walleye Capital
New York
$193K +$232K +20,050 New
Barclays
43
Barclays
United Kingdom
$184K -$63.9K -5,516 -22%
GCP
44
GSA Capital Partners
United Kingdom
$178K +$213K +18,398 New
Two Sigma Investments
45
Two Sigma Investments
New York
$167K +$201K +17,335 New
American Century Companies
46
American Century Companies
Missouri
$165K +$198K +17,107 New
EC
47
EntryPoint Capital
New York
$152K +$183K +15,801 New
VEA
48
Virtus ETF Advisers
New York
$129K -$10.6K -911 -6%
UBS Group
49
UBS Group
Switzerland
$129K +$1.52K +131 +1%
Citadel Advisors
50
Citadel Advisors
Florida
$127K -$2.3M -198,345 -94%
1
2
3 4

IGMS Hedge Fund Activity: Q1 2024 in Review

87 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in IGM Biosciences (IGMS) for Q1 2024, worth a combined $220M — up 20% from $183M a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new IGMS positions and 11 closed out — a net gain of 15 holders — while 21 added to existing stakes and 23 trimmed.

The largest buyer was T. Rowe Price Associates, adding an estimated $7.28M. The largest seller was Fidelity Investments, cutting an estimated $4.42M.

  • 87 institutional investors held IGM Biosciences (IGMS) as of Q1 2024, up from 72 in Q4 2023.
  • Funds reported $220M of IGM Biosciences stock for Q1 2024, up 20% quarter-over-quarter.
  • 26 funds opened new IGM Biosciences positions in Q1 2024 and 11 closed out, a net change of +15 holders.
  • The largest IGM Biosciences buyer in Q1 2024 was T. Rowe Price Associates, an estimated $7.28M added.
  • The largest IGM Biosciences seller in Q1 2024 was Fidelity Investments, an estimated $4.42M sold.

Based on aggregated 13F filings for Q1 2024.